We are live on ! Find out more
HUMA icon

Humacyte
HUMA

Fund managers haven’t disclosed any holdings of HUMA yet.

HUMA Hedge Fund Activity: Q1 2026 in Review

158 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Humacyte (HUMA) for Q1 2026, worth a combined $35.9M — down 32% from $53.1M a quarter earlier.

Buyers outnumbered sellers: 34 funds opened new HUMA positions and 19 closed out — a net gain of 15 holders — while 54 added to existing stakes and 29 trimmed.

The largest buyer was Antipodes Partners, adding an estimated $5.94M. The largest seller was Millennium Management, cutting an estimated $2.62M.

  • 158 institutional investors held Humacyte (HUMA) as of Q1 2026, up from 147 in Q4 2025.
  • Funds reported $35.9M of Humacyte stock for Q1 2026, down 32% quarter-over-quarter.
  • 34 funds opened new Humacyte positions in Q1 2026 and 19 closed out, a net change of +15 holders.
  • The largest Humacyte buyer in Q1 2026 was Antipodes Partners, an estimated $5.94M added.
  • The largest Humacyte seller in Q1 2026 was Millennium Management, an estimated $2.62M sold.

Based on aggregated 13F filings for Q1 2026.